Subscribe
istock-504614468_brauns
brauns / iStockphoto.com
4 December 2018Americas

Boehringer in research collaboration with Domain Therapeutics

German pharmaceutical company  Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business  Domain Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Boehringer signs deal to develop cystic fibrosis gene therapy
9 August 2018   Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Boehringer signs deal to develop cystic fibrosis gene therapy
9 August 2018   Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.

More on this story

Americas
Boehringer signs deal to develop cystic fibrosis gene therapy
9 August 2018   Boehringer Ingelheim has teamed up with academic institutions and research companies in the UK to develop a long-term gene therapy for cystic fibrosis, according to a statement released on Monday, August 6.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool